SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

2/9/24 9:03:02 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GBIO alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 GENERATION BIO COMMON STOCK Cusip #37148K100 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #37148K100 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,351,013 Item 6: 0 Item 7: 5,352,399 Item 8: 0 Item 9: 5,352,399 Item 11: 8.100% Item 12: HC Cusip #37148K100 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 5,352,399 Item 8: 0 Item 9: 5,352,399 Item 11: 8.100% Item 12: IN Item 1(a). Name of Issuer: GENERATION BIO Item 1(b). Address of Issuer's Principal Executive Offices: 301 Binney Street Cambridge, MA 02142 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 37148K100 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 5,352,399 (b) Percent of Class: 8.100% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 5,352,399 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of GENERATION BIO. No one other person's interest in the COMMON STOCK of GENERATION BIO is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA Fidelity Management Trust Company BK * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of GENERATION BIO at December 29, 2023. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $GBIO alert in real time by email

Recent Analyst Ratings for

$GBIO

Date	Price Target	Rating	Analyst
8/13/2025	$7.00	Outperform → Neutral	Wedbush
10/19/2023		Outperform → Market Perform	TD Cowen
11/8/2022	$9.00	Buy	Canaccord Genuity
12/15/2021	$40.00 → $10.00	Market Outperform	JMP Securities
12/15/2021	$50.00 → $27.00	Buy	Needham
12/14/2021		Outperform → Mkt Perform	William Blair

More analyst ratings

SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

2/9/24 9:03:02 AM ET

$GBIO

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $GBIO alert in real time by email

Recent Analyst Ratings for

$GBIO

Date	Price Target	Rating	Analyst
8/13/2025	$7.00	Outperform → Neutral	Wedbush
10/19/2023		Outperform → Market Perform	TD Cowen
11/8/2022	$9.00	Buy	Canaccord Genuity
12/15/2021	$40.00 → $10.00	Market Outperform	JMP Securities
12/15/2021	$50.00 → $27.00	Buy	Needham
12/14/2021		Outperform → Mkt Perform	William Blair

More analyst ratings

SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$GBIO

SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

Crush Q3 2025 with the Best AI Superconnector

Recent Analyst Ratings for
$GBIO

$GBIO
Insider Trading

CHIEF OPERATING OFFICER Paone Antoinette covered exercise/tax liability with 468 shares and converted options into 1,592 shares, increasing direct ownership by 3% to 35,465 units (SEC Form 4)

CHIEF LEGAL OFFICER Howze Yalonda converted options into 3,347 shares and covered exercise/tax liability with 983 shares, increasing direct ownership by 13% to 21,101 units (SEC Form 4)

Chief Financial Officer Conway Kevin John converted options into 587 shares and covered exercise/tax liability with 173 shares, increasing direct ownership by 2% to 18,273 units (SEC Form 4)

$GBIO
SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.

SEC Form 10-Q filed by Generation Bio Co.

Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$GBIO
Analyst Ratings

Generation Bio downgraded by Wedbush with a new price target

Generation Bio downgraded by TD Cowen

Canaccord Genuity initiated coverage on Generation Bio with a new price target

$GBIO
Insider Purchases

Director Quinn Anthony G. bought $203,209 worth of shares (210,791 units at $0.96), increasing direct ownership by 238% to 299,286 units (SEC Form 4)

Appelhans Dannielle bought $14,339 worth of shares (8,000 units at $1.79), increasing direct ownership by 5% to 12,637 units (SEC Form 4)

Appelhans Dannielle bought $18,000 worth of shares (12,000 units at $1.50) (SEC Form 4)

$GBIO
Press Releases

Generation Bio Announces New Data for Its Novel ctLNP Delivery System and Early T Cell Programs and Reports Second Quarter 2025 Financial Results

Generation Bio Announces 1-for-10 Reverse Stock Split

Generation Bio Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

$GBIO
Leadership Updates

Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

$GBIO
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

Amendment: SEC Form SC 13G/A filed by Generation Bio Co.